Knowledge Brief: Recent Evolution of Clinical Trial-Related Regulatory Environment in Belgium

Print this page         

by Nicolas Butz
Level: Intermediate

This Knowledge Brief provides information on the recent regulatory changes and clarifications that occurred in Belgium concerning the requirements related to the CTA and the declaration of Investigational Medicinal Products (IMPs). It also provides an overview of expectations to meet in order to run a clinical trial in Belgium, with references to the appropriate required documents.

Member Download now ( 2 MB)
Nonmember $5 / €3
Last Update: 19 September 2011

My ISPE

  • Click to go to My Communities of Practice
  • Click to go to My Affiliate or Chapter
  • Click to go to My Profile
Click to go to the Member Gift